Royalty Pharma (RPRX) Set to Post Quarterly Earnings on Wednesday

Royalty Pharma (NASDAQ:RPRX) will likely be releasing its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of $1.18 per share and revenue of $884.84 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:00 AM ET.

Royalty Pharma (NASDAQ:RPRX) last posted its earnings results on Wednesday, August 5th. The biopharmaceutical company reported $1.32 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.05. The firm had revenue of $674.14 million during the quarter, compared to the consensus estimate of $758.93 million. On average, analysts expect Royalty Pharma to post $5.29 EPS for the current fiscal year and $5.64 EPS for the next fiscal year.

Royalty Pharma Price Performance

Shares of NASDAQ:RPRX opened at $65.28 on Wednesday. The stock’s 50-day simple moving average is $59.96 and its two-hundred day simple moving average is $52.74. Royalty Pharma has a 52-week low of $35.92 and a 52-week high of $65.50.

Royalty Pharma Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a $0.2350 dividend. This represents a $0.94 annualized dividend and a dividend yield of 1.4%. The ex-dividend date is Friday, November 13th.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Morgan Stanley raised their price objective on shares of Royalty Pharma from $65.00 to $67.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. JPMorgan Chase & Co. boosted their target price on shares of Royalty Pharma from $58.00 to $62.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Weiss Ratings raised shares of Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday, September 14th. Bank of America reaffirmed a “buy” rating on shares of Royalty Pharma in a report on Wednesday, August 5th. Finally, TD Cowen increased their price target on shares of Royalty Pharma from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Tuesday, September 8th. Eight research analysts have rated the stock with a Buy rating. According to MarketBeat.com, Royalty Pharma presently has an average rating of “Buy” and an average target price of $61.57.

Insider Buying and Selling at Royalty Pharma

In other Royalty Pharma news, EVP Marshall Urist sold 4,126 shares of the business’s stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $57.10, for a total transaction of $235,594.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 100,000 shares of the business’s stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $58.53, for a total value of $5,853,000.00. Following the sale, the executive vice president directly owned 270,401 shares of the company’s stock, valued at $15,826,570.53. This represents a 27.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 208,252 shares of company stock worth $12,324,407 over the last quarter. 18.84% of the stock is owned by company insiders.

Royalty Pharma Company Profile

Royalty Pharma plc (NASDAQ:RPRX) is a biopharmaceutical royalty investment company that provides funding to life sciences companies, academic institutions, and other organizations in exchange for rights to future payments tied to approved or development-stage medicines. Its business model gives innovators access to capital while allowing Royalty Pharma to participate in the long-term commercial success of pharmaceutical products.

The company acquires and manages royalty interests across a broad range of therapeutic areas, including immunology, oncology, neuroscience, rare diseases, and infectious diseases.